Recruiting

Psoriasis Therapies

Sponsor:

CorEvitas

Code:

NCT02707341

Conditions

Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.

Conditions

Psoriasis

Study ID

NCT02707341

Start date

Apr, 2015

Status verified date

Aug, 2026

Completion date

Dec, 2100

Anticipated

Primary completion date

Dec, 2100

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

ELIGIBILITY CRITERIA∗ To be eligible for enrollment into the CorEvitas Psoriasis Registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below.

Inclusion Criteria:

The patient must:

1. Have been diagnosed with psoriasis by a dermatologist.
2. Be at least 18 years of age or older.
3. Be willing and able to provide written consent for participation in the registry.
4. Be willing and able to provide Personally Identifiable Information (PII) that includes the following types of personal information at a minimum: 1) Full Name and 2) Date of Birth.
5. Meet one of the following criteria.

Have started on or switched to a systemic psoriasis treatment within the previous 12 months†▲:

Exclusion Criteria:

1\. Patient is participating in or planning to participate in a double-blind randomized of a psoriasis drug. Of note, concurrent participation in another observational registry or open-label Phase 3b/4 trial is not excluded.

Study Design

Enrollment

10000 participants

Anticipated

Interventions and Outcome Measures

Arms

Psoriasis

Pts presenting to enrolling sites across the US are invited to enroll if eligible

Primary outcome measure

  • Number of patients with adverse events (AEs) or serious adverse events (SAEs). [ Time Frame: A minimum of 8 years from last patient enrolled ]

Central Contacts and Locations

Central contacts

Locations

Recruiting

Waltham, Massachusetts, United States, 02451

More Information

Sponsor

CorEvitas

Last update posted

Aug 27, 2026

Last verified

Aug, 2026

Keywords

  • psoriasis
  • disease registry

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by CorEvitas on 2026-08-27.